Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd (NQ: ROIV )

12.46 -0.06 (-0.52%)
Streaming Delayed Price Updated: 1:51 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,677,740
Open 12.71
Bid (Size) 12.46 (25)
Ask (Size) 12.47 (43)
Prev. Close 12.53
Today's Range 12.45 - 12.94
52wk Range 8.611 - 13.05
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
'I'm One Of You' – How 'Anti-Woke' Warrior Vivek Ramaswamy Became A Billionaire At Only 38
Via Benzinga
The Analyst Landscape: 5 Takes On Roivant Sciences
Via Benzinga

Performance

YTD
+9.82%
+9.82%
1 Month
+4.57%
+4.57%
3 Month
+5.81%
+5.81%
6 Month
+15.10%
+15.10%
1 Year
+36.98%
+36.98%

More News

Read More
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Earnings Scheduled For November 12, 2024
Via Benzinga
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
From Roivant Sciences
Via GlobeNewswire
Price Over Earnings Overview: Roivant Sciences
Via Benzinga
4 Analysts Assess Roivant Sciences: What You Need To Know
Via Benzinga
Evaluating Roivant Sciences: Insights From 6 Financial Analysts
Via Benzinga
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Roivant Sciences
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Organon, Howmet Aerospace And More: CNBC's 'Final Trades'
Via Benzinga
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Via Benzinga
The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
Via Benzinga
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
From Roivant Sciences
Via GlobeNewswire
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
Via Benzinga
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress
From Roivant Sciences
Via GlobeNewswire
Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator
From Roivant Sciences
Via GlobeNewswire
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Via Benzinga
Roivant Provides Update on Graves’ Disease Development Program
From Roivant Sciences
Via GlobeNewswire
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
Via Investor's Business Daily
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
From Roivant Sciences
Via GlobeNewswire
ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024
Via InvestorPlace
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
From Roivant Sciences
Via GlobeNewswire
Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.